Abstract
Three generations of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) have been developed to treat advanced non-small cell lung cancer (NSCLC) patients harboring EGFR-activating mutations. Although initially effective, multiple resistance mechanisms developed. Therefore, the combination with other therapeutic agents has emerged as a promising strategy to overcome resistance. However, no meta-analysis compared the efficacy and safety of different EGFR-TKI generations in combination with antiangiogenic, thus results remain elusive.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
